{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-036006","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.538750+00:00","generated_at":"2026-06-04T08:35:29.445224+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tivic Health FY 2023 revenue down 36% to $1.2M; net loss narrows to $8.2M","bullets":["Revenue $1.2M (-36% YoY) on 52% fewer unit sales; ASP up 46%.","Net loss improved to $8.2M from $10.1M; cash $3.4M, no debt.","Raised $7.9M via two public offerings in 2023; executed 1-for-100 reverse split and regained Nasdaq compliance.","Completed enrollment for VNS pilot study in Feb 2024; results pending.","Named to Fast Company's Most Innovative Companies 2023 in Medical Device."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-036006","json":"https://secwatch.observer/filing/0000950170-24-036006.json","markdown":"https://secwatch.observer/filing/0000950170-24-036006.md","text":"https://secwatch.observer/filing/0000950170-24-036006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017024036006/0000950170-24-036006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017024036006/tivc-20240325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:35:29.445224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44533cef5f05f4462fb3d59f16c416f58661a521","claim":"Valion Bio, Inc. reported the year ending December 31, 2023 results: revenue $1.2M, net income net loss was $8.2M.","evidence_excerpt":"and Global Health & Pharma (GHP) named Tivic Health the Most Pioneering Bioelectronic Medicine Company. 2023 Financial Performance • Revenue (net of returns) for 2023 was $1.2M compared to $1.8M for the year ended December 31, 2022. The decrease of $664 thousand, or 36%, was due to a 52% decrease in ClearUP unit sales, offset by 46% higher average","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787740/000095017024036006/0000950170-24-036006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ending December 31, 2023"},{"label":"Revenue","value":"$1.2M"},{"label":"Net income","value":"net loss was $8.2M"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}